Form S-8 Karyopharm Therapeutics
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Karyopharm Therapeutics (KPTI) PT Raised to $22 at Baird; 'Expect a transformational year'
March 15, 2018 2:01 PM EDTBaird raised its price target on Karyopharm Therapeutics (NASDAQ: KPTI) to $22.00 (from $15.00) while maintaining a Outperform rating.
Analyst Michael E. Ulz commented, "Recent progress across the selinexor franchise was highlighted, and management indicated initial commercial preparations are underway, a positive sign, in... More
